NTM Info and Research Inc.

View our webinar series
and more educational videos

Watch Now

NTM Info & Research Welcomes
Attorney and Rare Disease Advocate,
Candace Lerman to Board of Directors

ARISE/ENCORE
Clinical Trial Program for MAC Lung Disease

Learn about visual acuity testing

NTMir Awards Grant to

Oregon Health & Science University

Join the Phase 3 trial of CleaR-Mac – RHB-204 for the Treatment of
Pulmonary Mycobacterium Avium Complex Disease

Join Clinical Trial

European Union approves Arikayce

inhaled liposomal amikacin

We Launched a Companion
Website for Bronchiectasis

See Website

NOW AVAILABLE

"INSIGHT" A Patients Perspective

Insight into the lung disease caused by nontuberculous mycobacteria (NTM),
and empowers the patient to participate in his or her own treatment.

AVAILABLE IN VARIOUS LANGUAGES, REQUEST YOUR COPY TODAY.

Nontuberculous Mycobacteria (NTM Disease) | Woman Breathing with Lungs Expanding

A Physician’s Perspective

by Ed Chan, MD

DOWNLOAD

Airway clearance therapy is an integral part of daily lung care and respiratory hygiene

LEARN MORE

STAY INFORMED

Click here to sign up for the latest news on NTMir

WHO WE ARE

NTMir advances a broad agenda on behalf of people with nontuberculous mycobacterial (NTM) disease, as well as healthcare providers, researchers….

SUPPORT GROUPS

Whether it’s a local support group, online forums where you can exchange ideas with other patients, or links to other useful resources, you’ve come to the right place.

"INSIGHT" PATIENT PAMPHLET

Print or download our informative “Insight” pamphlet in multiple languages and keep the knowledge you need at your fingertips.

PHYSICIAN REFERRAL LIST

Find experts in the care you need with our Physician Referral List.

TAKE ACTION

We are stronger as a community than we are alone. Your voice added to ours helps us accomplish our mission.

DONATE

We are supported by patients’ actions and donations, industry, and others who care about those with NTM lung disease.

NTMir’s mission is to save and improve lives through research, education, early detection, and improved treatments for people with pulmonary nontuberculous mycobacterial infection (NTM disease).

Estimated cases of NTM in the US in 2020

0.2 %

The rise in the number of NTM cases each year

0.8 million

Antibiotic-resistant infections in the US each year